130 related articles for article (PubMed ID: 38906557)
1. Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
Bauckneht M; Lanfranchi F; Albano D; Triggiani L; Linguanti F; Urso L; Mazzola R; Rizzo A; D'Angelo E; Dondi F; Mataj E; Pedersoli G; Abenavoli EM; Vaggelli L; Detti B; Ortolan N; Malorgio A; Guarneri A; Garrou F; Fiorini M; Grimaldi S; Ghedini P; Iorio GC; Iudicello A; Rovera G; Fornarini G; Bongiovanni D; Marcenaro M; Pazienza FM; Timon G; Salgarello M; Racca M; Bartolomei M; Panareo S; Ricardi U; Bertagna F; Alongi F; Barra S; Morbelli S; Sambuceti G; Belgioia L
J Nucl Med; 2024 Jun; ():. PubMed ID: 38906557
[TBL] [Abstract][Full Text] [Related]
2. PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.
Bianchi L; Ceci F; Balestrazzi E; Costa F; Droghetti M; Piazza P; Pissavini A; Presutti M; Farolfi A; Mei R; Castellucci P; Gandaglia G; Larcher A; Robesti D; Mottrie A; Briganti A; Morganti AG; Fanti S; Montorsi F; Schiavina R; Brunocilla E
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046687
[TBL] [Abstract][Full Text] [Related]
3. Oligometastatic Prostate Cancer Treated with Metastasis-Directed Therapy Guided by Positron Emission Tomography: Does the Tracer Matter?
Lanfranchi F; Belgioia L; Marcenaro M; Zanardi E; Timon G; Riondato M; Giasotto V; Zawaideh JP; Tomasello L; Mantica G; Piol N; Borghesi M; Traverso P; Satragno C; Panarello D; Scaffidi C; Romagnoli A; Rebuzzi SE; Coco A; Spina B; Morbelli S; Sambuceti G; Terrone C; Barra S; Fornarini G; Bauckneht M
Cancers (Basel); 2023 Jan; 15(1):. PubMed ID: 36612319
[TBL] [Abstract][Full Text] [Related]
4. Metastasis-directed Therapy (SBRT) Guided by PET-CT
Mazzola R; Francolini G; Triggiani L; Napoli G; Cuccia F; Nicosia L; Livi L; Magrini SM; Salgarello M; Alongi F
Clin Genitourin Cancer; 2021 Jun; 19(3):230-236. PubMed ID: 32863189
[TBL] [Abstract][Full Text] [Related]
5. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
De Bruycker A; Spiessens A; Dirix P; Koutsouvelis N; Semac I; Liefhooghe N; Gomez-Iturriaga A; Everaerts W; Otte F; Papachristofilou A; Scorsetti M; Shelan M; Siva S; Ameye F; Guckenberger M; Heikkilä R; Putora PM; Zapatero A; Conde-Moreno A; Couñago F; Vanhoutte F; Goetghebeur E; Reynders D; Zilli T; Ost P
BMC Cancer; 2020 May; 20(1):406. PubMed ID: 32398040
[TBL] [Abstract][Full Text] [Related]
6. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
Glicksman RM; Metser U; Vines D; Valliant J; Liu Z; Chung PW; Bristow RG; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Green D; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
Eur Urol; 2021 Sep; 80(3):374-382. PubMed ID: 33685838
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Hormone-Sensitive Oligorecurrent Prostate Cancer Patients Based on Routine Use of Choline and/or PSMA PET/CT to Guide Metastasis-Directed Therapy.
Metz R; Rauscher A; Vaugier L; Supiot S; Drouet F; Campion L; Rousseau C
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980784
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes of metastasis-directed treatment using
Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer.
Murad V; Glicksman RM; Berlin A; Santiago A; Ramotar M; Metser U
Radiology; 2023 Dec; 309(3):e231407. PubMed ID: 38051188
[TBL] [Abstract][Full Text] [Related]
12. SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
Rans K; Charlien B; Filip A; Olivier H; Julie DH; Céderic D; Herlinde D; Benedikt E; Karolien G; Annouschka L; Nick L; Kenneth P; Carl S; Koen S; Hans V; Ben V; Steven J; Gert M
BMC Cancer; 2022 Dec; 22(1):1294. PubMed ID: 36503429
[TBL] [Abstract][Full Text] [Related]
13. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [
Vogel MME; Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Mix M; la Fougère C; Eiber M; Christiansen H; Belka C; Grosu AL; Müller AC; Guckenberger M; Combs SE
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2328-2338. PubMed ID: 32179961
[TBL] [Abstract][Full Text] [Related]
14. Combining
Kirste S; Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Becker J; Zamboglou C; Burger I; Derlin T; Bartenstein P; Ruf J; la Fougère C; Eiber M; Christiansen H; Combs SE; Müller AC; Belka C; Guckenberger M; Grosu AL
Front Oncol; 2021; 11():640467. PubMed ID: 34041020
[TBL] [Abstract][Full Text] [Related]
15. The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence.
Bianchi L; Ceci F; Costa F; Balestrazzi E; Droghetti M; Piazza P; Pissavini A; Mei R; Farolfi A; Castellucci P; Puliatti S; Larcher A; Gandaglia G; Robesti D; Mottrie A; Briganti A; Morganti AG; Fanti S; Montorsi F; Schiavina R; Brunocilla E
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612242
[TBL] [Abstract][Full Text] [Related]
16. Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy.
Devos G; Berghen C; Van Eecke H; Stichele AV; Van Poppel H; Goffin K; Mai C; De Wever L; Albersen M; Everaerts W; De Meerleer G; Joniau S
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32823690
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
[TBL] [Abstract][Full Text] [Related]
18. ML Models Built Using Clinical Parameters and Radiomic Features Extracted from
Urso L; Cittanti C; Manco L; Ortolan N; Borgia F; Malorgio A; Scribano G; Mastella E; Guidoboni M; Stefanelli A; Turra A; Bartolomei M
Diagnostics (Basel); 2024 Jun; 14(12):. PubMed ID: 38928679
[TBL] [Abstract][Full Text] [Related]
19. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
[TBL] [Abstract][Full Text] [Related]
20. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P; Reynders D; Decaestecker K; Fonteyne V; Lumen N; De Bruycker A; Lambert B; Delrue L; Bultijnck R; Claeys T; Goetghebeur E; Villeirs G; De Man K; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; De Meerleer G
J Clin Oncol; 2018 Feb; 36(5):446-453. PubMed ID: 29240541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
